within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01C_BetaLactamAntibacterialsPenicillins.J01CF01_Dicloxacillin;

model Dicloxacillin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.5,
    Cl = 2.3888888888888887e-06,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.01,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.015500000000000002,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dicloxacillin</td></tr><tr><td>ATC code:</td><td>J01CF01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>10</td><td>L</td></tr>
    <tr><td>clearance:</td><td>8.6</td><td>L/hr</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dicloxacillin is a narrow-spectrum beta-lactam antibiotic of the penicillin class, used primarily to treat infections caused by penicillinase-producing staphylococci. It is active against Gram-positive bacteria and is approved for clinical use in many countries for conditions such as skin and soft tissue infections.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after single oral dosing.</p><h4>References</h4><ol><li><p>Bock, M, et al., &amp; Moser, C (2023). Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 77(2) 242–251. DOI:<a href=\"https://doi.org/10.1093/cid/ciad168\">10.1093/cid/ciad168</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36947131/\">https://pubmed.ncbi.nlm.nih.gov/36947131</a></p></li><li><p>Wu, G, et al., &amp; Shentu, J (2015). Safety and pharmacokinetics of dicloxacillin in healthy Chinese volunteers following single and multiple oral doses. <i>Drug design, development and therapy</i> 9 5687–5695. DOI:<a href=\"https://doi.org/10.2147/DDDT.S92117\">10.2147/DDDT.S92117</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26527863/\">https://pubmed.ncbi.nlm.nih.gov/26527863</a></p></li><li><p>Langtry, HD, &amp; Balfour, JA (1998). Azithromycin. A review of its use in paediatric infectious diseases. <i>Drugs</i> 56(2) 273–297. DOI:<a href=\"https://doi.org/10.2165/00003495-199856020-00014\">10.2165/00003495-199856020-00014</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9711451/\">https://pubmed.ncbi.nlm.nih.gov/9711451</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01CF01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dicloxacillin;
